• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Results from the REFLECT II Trial reported at TCT Connect
(Cardiovascular Research Foundation) The REFLECT II randomized clinical trial evaluating the safety and efficacy of a device designed to reduce cerebral embolization and ischemic stroke, complications of transcatheter aortic valve replacement (TAVR), found that the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority of the device for the primary hierarchical efficacy endpoint.
Source: EurekAlert! - Medicine and Health - October 15, 2020 Category: International Medicine & Public Health Source Type: news

TAVR equivalent to surgery at 2 years among low-risk patients
(American College of Cardiology) Patients undergoing transcatheter aortic valve replacement (TAVR) fared equally well compared with those undergoing open heart valve replacement surgery in terms of the combined risk of death, stroke or rehospitalization at two years, the primary endpoint of the PARTNER 3 trial being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

TAVR shows favorable safety in patients with bicuspid valve
(American College of Cardiology) Transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days in patients with a bicuspid, or two-leaflet, aortic valve, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

NEJM: transcatheter aortic valve replacement shows similar safety outcomes as open-heart surgery
(Cedars-Sinai Medical Center) A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement (TAVR), had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve.
Source: EurekAlert! - Medicine and Health - January 29, 2020 Category: International Medicine & Public Health Source Type: news

Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR
(Society for Cardiovascular Angiography and Interventions) Results from 'Effect of bivalirudin versus unfractionated heparin in patients with baseline or new-onset atrial fibrillation in transcatheter aortic valve replacement: From the BRAVO-3 randomized trial' were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.
Source: EurekAlert! - Social and Behavioral Science - May 11, 2017 Category: International Medicine & Public Health Source Type: news

Self-expanding TAVR as good as surgery in intermediate-risk patients
(American College of Cardiology) Two-year data reveal no difference in the combined rate of stroke and death from any cause when comparing the use of self-expanding transcatheter aortic valve replacement (TAVR) with standard open-heart surgery in intermediate risk patients with severe aortic stenosis, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.
Source: EurekAlert! - Medicine and Health - March 17, 2017 Category: Global & Universal Source Type: news

Intra-hospital correlations among 30-day mortality rates in 18 different clinical and surgical settings
Conclusions</div>The variability in 30-day mortality rates at hospital level and the correlation between risk mortality rates suggest that there may be common hospital-wide factors influencing short-term mortality.</span>
Source: International Journal for Quality in Health Care - January 31, 2017 Category: Global & Universal Source Type: research

Yale leads test of new device that protects the brain during heart-valve procedure
(Yale University) In the first multicenter trial of its kind, Yale researchers tested a new device that lowers the risk of stroke and cognitive decline in patients undergoing heart-valve replacement.
Source: EurekAlert! - Medicine and Health - March 15, 2015 Category: Global & Universal Source Type: news

Results of the REPRISE II trial reported at TCT 2013
(Cardiovascular Research Foundation) In a clinical trial, a second-generation transcatheter aortic valve demonstrated low rates of complications that are sometimes seen in transcatheter aortic valve replacement, including challenges with positioning, post-procedure paravalvular aortic regurgitation, vascular complications, and stroke.
Source: EurekAlert! - Medicine and Health - October 31, 2013 Category: Global & Universal Source Type: news

Results of the COREVALVE EXTREME RISK trial presented at TCT 2013
(Cardiovascular Research Foundation) In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery. Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Source: EurekAlert! - Medicine and Health - October 29, 2013 Category: Global & Universal Source Type: news

Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk
(American Association for Thoracic Surgery) Investigators show that lower dose anticoagulation therapy, combined with low-dose aspirin, resulted in a reduction of 55 to 60 percent of the incidence of adverse bleeding events without significant increases in stroke, transient ischemic attack or total neurological events when used in conjunction with the On-X mechanical aortic valve.
Source: EurekAlert! - Medicine and Health - May 6, 2013 Category: Global & Universal Source Type: news